On September 25, 2018 SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, reported that the Company will present at the following upcoming investor conferences (Press release, Scynexis, SEP 25, 2018, View Source [SID1234529571]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Ladenburg Thalmann 2018 Healthcare Conference at the Sofitel New York on Tuesday, October 2, 2018 at 10:30 a.m. ET.
Cantor Fitzgerald’s Global Healthcare Conference at InterContinental New York Barclay on Wednesday, October 3, 2018 at 2:15 p.m. ET.
Live webcasts of the presentations will be available on the Investors section of the Company’s website: www.scynexis.com. A replay of each presentation will be available approximately two hours after the event and will be available for two weeks following each presentation.

On September 25, 2018 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that members of the Company’s management team will participate in the following upcoming investor conferences (Press release, Karyopharm, SEP 25, 2018, View Source [SID1234529570]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 2:50 p.m. ET.

The Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018 at 9:00 a.m. ET.
A live webcast of each of these events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of each webcast will be archived on the Company’s website for 90 days following the presentation.

On September 25, 2018 DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3 at 1:40 p.m. Eastern Time (Press release, DURECT, SEP 25, 2018, http://investors.durect.com/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=2368790 [SID1234529569]). The conference is being held at the InterContinental New York Barclay hotel in New York City. Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available by accessing View Source

A live audio webcast of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT’s website under Audio Archive in the "Investor Relations" section.

On September 25, 2018 Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, reported that CFO and Head of Corporate Strategy, John Leaman, M.D., will present at the Cantor Fitzgerald Global Healthcare Conference in New York City at 5:10 p.m. ET on Tuesday, October 02, 2018 (Press release, Selecta Biosciences, SEP 25, 2018, View Source [SID1234529568]). A live and archived webcast of the presentation can be accessed via the Investors & Media section of the company’s website, View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 25, 2018 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that management will present at two upcoming investor conferences in October (Press release, Fate Therapeutics, SEP 25, 2018, View Source [SID1234529567]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Cantor Global Healthcare Conferenceat 9:10 a.m. ET on Tuesday, October 2, 2018 in New York City.
Leerink Partners Roundtable Series: Rare Disease & Oncology at 8:30 a.m. ET on Wednesday, October 3, 2018 in New York City.

Live webcasts of the presentations will be available through the investor relations section of the Company’s website at www.fatetherapeutics.com. Following the live webcasts, an archived replay will be available on the Company’s website.